Ark Biosciences, a Shanghai-Suzhou clinical-stage biotech, will release unblinded clinical efficacy results from a global trial of ziresovir, a treatment for RSV in hospitalized infants. The results, which come from Part 1 of a global Phase II proof-of-concept ziresovir trial, will be presented at two scientific meetings over the next two weeks. Ark in-licensed global rights to the candidate from Roche in 2014.
Source: China Biotoday
